Osobennosti terapii narusheniy mocheispuskaniy u zhenshchin v klimakterii (obzor literatury)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents a literature review reflecting the modern potentials for the therapy of overactive bladder in women depending on age. The lower urogenital tract is sensitive to sex steroids, whose importance in the genesis of the symptoms of overactive bladder is not in doubt. The problems of the introduction of different types of hormone replacement therapy in the complex therapy are considered.

Full Text

Restricted Access

References

  1. Legendre G., Ringa V., Fauconnier A. Menopause, hormone treatment and urinary incontinence at midlife. Maturitas. 2013;74:26-30.
  2. Temml C., Haidinger G., Schmidbauer J., Schatzl G., Madersbacher S. Urinary incontinence in both sexes: prevalence rates and impact on quality of life and sexual life. Neurourol. Urodyn. 2000;19(3):259-71.
  3. Sand P.K., Goldberg R.P., Dmochowski R.R., McIlwain M., Dahl N.V. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am. J. Obstet. Gynecol. 2006;195:1730.
  4. McGrother C.W., Donaldson M.M., Shaw C., Matthews R.J., Hayward T.A., Dallosso H.M., Jagger C., Clarke M., Castleden C.M.; MRC Incontinence Study Team. Storage symptoms of the bladder: prevalence, incidence and need for services in the UK. BJU International, 2004;93:763-69.
  5. Hagglund D., Walker-Engstrom M.L., Larsson G., Leppert J. Changes in urinary incontinence and quality of life after four years. A population-based study of women aged 22-50 years. Scandinavian Journal of Primary Health Care. 2004;22:112-17.
  6. Sherburn M., Guthrie J.R., Dudley E.C., O'Connell H.E., Dennerstein L. Is incontinence associated with menopause? Obstetrics and Gynecology. 2001;98:628-33.
  7. Townsend M.K., Danforth K.N., Lifford K.L., Rosner B., Curhan G.C., Resnick N.M., Grodstein F. Incidence and remission of urinary incontinence in middle-aged women. Am. J. Obstet. Gynecol. 2007;97:1671-75.
  8. Moller L.A., Lose G., Jorgensen T. Incidence and remission rates of lower urinary tract symptoms at one year in women aged 40-60: longitudinal study. Br. Med. J. 2000;320:1429-32.
  9. Waetjen L.E., Ye J., Feng W.Y., Johnson W.O., Greendale G.A., Sampselle C.M., Sternfield B., Harlow S.D., Gold E.B. Study of Women's Health Across the Nation (SWAN).Association between menopausal transition stages and developing urinary incontinence. Obstet. Gynecol. 2009;114:989-98.
  10. Waetjen L.E., Feng W.Y., Ye J., Johnson W.O., Greendale G.A., Sampselle C.M., Sternfield B., Harlow S.D., Gold E.B. Study of Women's Health Across the Nation (SWAN). Factors associated with worsening and improving urinary incontinence across the menopausal transition. Obstet. Gynecol. 2008;111:667-77.
  11. Mishra G.D., Cardozo L., Kuh D. Menopausal transition and the risk of urinary incontinence: results from a British prospective cohort. BJU International. 2010;106:1170-75.
  12. Zhu L., Lang J., Liu C., Han S., Huang J., Li X. The epidemiological study of women with urinary incontinence and risk factors for stress urinary incontinence in China. Menopause. 2009;16:831-36.
  13. Gopal M., Sammel M.D., Arya L.A., Freeman E.W., Lin H., Gracia C. Association of change in estradiol to lower urinary tract symptoms during the menopausal transition. Obstet. Gynecol. 2008;112:1045-52.
  14. Waetjen L.E., Johnson W.O., Xing G., Feng W.Y., Greendale G.A., Gold E.B.; Study of Women's Health Across the Nation. Serum estradiol levels are not associated with urinary incontinence in midlife women transitioning through menopause. Menopause. 2011;8:1283-90.
  15. Teleman P.M., Persson J., Mattiasson A., et al. The relation between urinary incontinence and steroid hormone levels in perimenopausal women. A report from the Women's Health in the Lund Area (WHILA) study. Acta Obstetricia et Gynecologica Scandinavica. 2009; 88:927-32.
  16. Карлсон Б. Основы эмбриологии по Пэттену. М., 1983;2:168-80.
  17. Gosling J.A., Dixon J. Embryology and ultrastructur of the female lower urinary tract in: Urogynecology and urodinamic. Theory and Practice. Edited by Donald R. Ostergard, A.E. Bent, Baltimore. 1991;19-30.
  18. Estrogen and progestogen use in postmenopausal women: position statement of The North American Menopause Society. J. North Am. Menopause Society. 2008;4:584-603.
  19. Балан В.Е., Ковалева Л.А. Гормоны и урогенитальный эпителий. Глава в руководстве для практикующих врачей «Шейка матки, влагалище, вульва» под ред. С.И. Роговской, Е.В. Липовой. Status praesens, 2014;741-77.
  20. Cavallini E., Dinaro A., Giocolano C., Caringella A.M., Ferreri R., Tutino V., Loverro G. Estrogen receptor (ER) and ER-related receptor expressoin in normal and atrophic human vagina. Maturitas. 2008;219-25.
  21. Position statement. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20(9):888-902.
  22. Gormley A.E., Lightner D.J., Burgio K.L., et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline, 2014.
  23. Chapple C.R., Khullar V., Gabriel Z., Muston D., Bitoun C.E., Weinstein D. The effects of anti-muscarinic treatments in overactive bladder: an update of a systematic review and metaanalysis. Eur. Urol. 2008;54:543.
  24. Novara G., Galfano A., Secco S., D'Elia C., Cavalleri S., Ficarra V., Artibani W. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur. Urol. 2008;54:740.
  25. Al-Baghdadi O., Ewies A. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric. 2009;91-105.
  26. Cardozo L., Lose G., McClish D., Versi E. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstetricia Gynecologica Scandinavica. 2004;83:892-97.
  27. Ewies A.A., Alfhaily F. Topical vaginal estrogen therapy in managing postmenopausal urinary symptoms: a reality or a gimmick? Climacteric. 2010;13:405-18.
  28. Ледина А.В., Прилепская В.Н., Костава М.Н., Назарова Н.М. Лечение атрофических вульвовагинитов у женщин в постменопаузе. Гинекология. 2012;12(4):14-16.
  29. Новикова В.А., Федорович О.К., Атанеcян Э.Г. Овестин - в комплексной терапии уровагинальной атрофии пременопаузального у женщин с преждевременной недостаточностью функции яичников. Гинекология. 2009;1(11):60-62.
  30. Балан В.Е. Клиническая картина, диагностика и лечение вагинальной атрофии в климактерии. Гинекология. 2009;2( 11):26-29.
  31. Serati M., Salvatore S., Uccella S., Cardozo L., Bolis P. Is there a synergistic effect of topical oestrogens when administered with antimus-carinics in the treatment of symptomatic detrusor overactivity? Eur. Urol. 2009;55:713-19.
  32. Nelken R.S., Ozel B.Z., Leegant A.R., Felix J.C., Mishell D.R. Jr. Randomized trial of estradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause. 2011;18:962-66.
  33. Tseng L.H., Wang A.C., Chang Y.L. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. Neurourol. Urodynam. 2009;28:47-51.
  34. Legendre G., Ringa V., Fauconnier A. Menopause, hormone treatment and urinary incontinence at midlife. Maturitas. 2013;74:26-30.
  35. Hendrix S.L., Cochrane B.B., Nygaard I.E., Han da V.L., Barnabei V.M., Iglesia C., Aragaki A., Naughton M.J., Wallace R.B., McNeeley S.G. Effects of estrogen with and without progestin on urinary incontinence. J. Am. Med. Associat. 2005;293:935-48.
  36. Steinauer J.E., Waetjen L.E., Vittinghoff E., Subak L.L., Hulley S.B., Grady D., Lin F., Brown J.S. Postmenopausal hormone therapy: does it cause incontinence? Obstet. Gynecol. 2005;106:940-45.
  37. Cody J.D., Richardson K., Moehrer B., Hextall A., Glazener C.M. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database of Systematic Reviews. 2009;CD001405.
  38. Grodstein F., Lifford K., Resnick N.M. Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstetrics and Gynecology. 2004;103:254-60.
  39. Northington G.M., de Vries H.F., Bogner H.R. Self-reported estrogen use and newly incident urinary incontinence among postmenopausal community-dwelling women. Menopause. 2012;19:290-95.
  40. Liapis A., Bakas P., Georgantopoulou C., Creatsas G. The use of oestradiol therapy in postmenopausal women after TVT-O anti-incontinence surgery. Maturitas. 2010;66:101-06.
  41. Zullo M.A., Plotti F., Calcagno M., Palaia I., Muzii L., Manci N., Angioli R., Panici P.B. Vaginal estrogen therapy and overactive bladder symptoms in postmenopausal patients after a tension-free vaginal tape procedure: a randomized clinical trial. Menopause. 2005;12:421-27.
  42. Fritel X., Ringa V., Quiboeuf E., Fauconnier A. Female urinary incontinence, from pregnancy to menopause, a review of epidemiologic and pathophysiologic findings. Acta Obstetricia Gynecologica Scandinavica. 2012; 91:901-10.
  43. Ewies A.A., Alfhaily F. Topical vaginal estrogen therapy in managing postmenopausal urinary symptoms: a reality or a gimmick? Climacteric. 2010;13:405-18.
  44. Robinson D., Cardozo L. Estrogens and the lower urinary tract. Neurourol. Urodynam. 2011;30:754-57.
  45. Thuroff J. W., Abrams P., Andersson K.E., Artibani W., Chapple C.R., Drake M.J., Hampel C., Neisius A., Schröder A., Tubaro A. EAU guidelines on urinary incontinence. Eur. Urol. 2011;59:387-400.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies